Dyslipidemia and Kidney: An Updated View

Dyslipidemia and Kidney

Abstract views: 133 / PDF downloads: 70





Chronic kidney disease, dialysis, dyslipidemia, nephrotic syndrome, statins, transplantation


Dyslipidemia is a common concern in various kidney-related conditions, including chronic kidney disease, nephrotic syndrome, kidney transplant patients, and those undergoing dialysis. Dyslipidemia is a significant risk factor for atherosclerosis and cardiovascular diseases in these patient groups. Understanding the unique challenges and factors associated with dyslipidemia in these kidney-related conditions is essential for providing effective patient care and reducing cardiovascular risk. This review explores the relationship between dyslipidemia and kidney diseases, highlighting the key recommendations and considerations for managing lipid profiles in each population.


Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290(2):F262-F272. doi:10.1152/ajprenal.00099.2005

Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S142-S156. doi:10.1053/ajkd.1998.v32.pm9820472

Kidney disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Inter., Suppl. 2013; 3: 259–305.

Mach F, Colin B, Catapano AL, et al. “2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk.” Atherosclerosis. 290 2019: 140-205.

Navaneethan SD, Schold JD, Walther CP, et al. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J of Clin Lipid. 2018;12(4):1061-1071.

Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78(5):572-575.

Schmit D, Fliser D, Speer T. Proprotein convertase subtilisin/kexin type 9 in kidney disease. Nephrol Dial Transplant. 2019;34(8):1266–1271.

Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl J Med. 2005 Oct 13;353(15):1640]. N Engl J Med. 2005;353(3):238-248. doi:10.1056/NEJMoa043545

Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis [published correction appears in N Engl J Med. 2010 Apr 15;362(15):1450]. N Engl J Med. 2009;360(14):1395-1407. doi:10.1056/NEJMoa0810177

Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263-275. doi:10.7326/0003-4819-157-4-201208210-00007

Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807-1817. doi:10.1093/eurheartj/eht065

Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000;70(9):1352-1359. doi:10.1097/00007890-200011150-00015

Kockx, Maaike, and Leonard Kritharides. “Cyclosporin A-induced hyperlipidemia.” Lipoproteins-Role in Health and Diseases. Rijeka: InTech Publishers (2012): 337-354.

Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036-1042. doi:10.1097/00007890-199904150-00017

Holdaas H, Fellström B, Jardine AG, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005;20(5):974-980. doi:10.1093/ndt/gfh735

Kim JJ, David JM, Wilbon SS, et al. Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome. EBioMedicine. 2021;63:103162. doi:10.1016/j.ebiom.2020.103162

Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323(9):579-584. doi:10.1056/NEJM199008303230905

Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590. doi:10.1001/jama.292.21.2585




How to Cite

Can, Özgür. (2024). Dyslipidemia and Kidney: An Updated View: Dyslipidemia and Kidney. Journal of European Internal Medicine Professionals, 2(1). https://doi.org/10.5281/zenodo.10654236



Review or Metaanalysis